Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Sorafenib is a multikinase inhibitor used in solid tumor treatment, but its molecular targets and effective combination strategies remain unclear.
• Identifying novel targets and synergistic combinations is crucial for improving sorafenib's clinical efficacy.

Purpose of the Study:

• To identify the molecular targets of sorafenib.
• To investigate the synergistic effect of sorafenib and metformin in non-small cell lung cancer (NSCLC).

Main Methods:

• Sorafenib's effect on AMP-activated protein kinase (AMPK) was assessed.
• A Phase II clinical trial evaluated sorafenib combined with metformin in KRAS-mutant advanced NSCLC patients.
• In vitro and in vivo studies examined the synergistic effects on cellular proliferation and AMPK activation.

Main Results:

• Sorafenib was identified as an activator of AMPK, involving LKB1 or CAMKK2.
• The combination of sorafenib and metformin demonstrated an improved disease control rate in NSCLC patients.
• Synergistic inhibition of cellular proliferation and enhanced AMPK activation were observed in vitro and in vivo.

Conclusions:

• Sorafenib activates the AMPK pathway, providing a rationale for combination therapies.
• Combining sorafenib with AMPK activators like metformin shows synergistic anti-tumor effects in NSCLC.
• This combination strategy warrants further investigation in prospective clinical trials for solid tumors.